The novel coronavirus is dominating headlines around the world right now. But in Maxim Group’s latest report on Inovio Pharmaceuticals (INO), COVID-19 merits hardly a mention. Turns out, Maxim loves this stock, but not only because of Coronavirus.In Maxim’s note, analyst Jason McCarthy notes that “it’s too early to tell” if Inovio is “a COVID-19 play.” On the one hand, “Inovio has rapidly developed its DNA-based COVID-19 vaccine, INO-4800.” Within just three hours of receiving its first sample of the virus’s genetic sequence, Inovio already had the vaccine candidate prepared “using its DNA-based vaccine platform,” and began “preclinical development.”Like Novavax …read more
Source:: Yahoo Finance
